Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AMA on health claims

This article was originally published in The Tan Sheet

Executive Summary

American Medical Association "strongly opposes" FDA's decision to "allow a lower standard - the so-called weight of the scientific evidence standard - to be used in deciding whether a health claim can be placed on the labeling of a conventional food product," according to Feb. 21 comments. The "weight of the scientific evidence standard" would allow the use of health claims "that have a reasonable chance of being erroneous" and "actually could confuse consumers" rather than help them to make informed decisions, the medical group contends. Comments respond to FDA's decision to no longer hold health claims for food, supplements to significant scientific agreement standard (1"The Tan Sheet" Dec. 23, 2002, p. 10). AMA also says it is working with Congress to modify DSHEA...

You may also be interested in...

Qualified Health Claims “Reasonable Consumer” Standard Adopted By FDA

FDA will employ a "reasonable consumer" standard, rather than an "ignorant, unthinking and credulous" consumer standard, to determine whether dietary supplement and food labeling is misleading, the agency announced Dec. 18

Health And Wellness Trademark Review 18 February, 2020

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Genfit Delays NASH Data While It Confers With US FDA On Methodology

Genfit will delay unblinding of data from its nearly complete Phase III study of elafibranor to get insight from the FDA on statistical methods in order to optimize its NDA.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts